The 2026 ESCRS meeting in Copenhagen was a highly successful and busy event for Glaukos, highlighted by the launch of iStent infinite®. The new device was prominently featured across podium presentations, booth speaker sessions, and hands-on dry labs, following its recent MDR CE mark approval in both Europe and the UK.
Early iStent Infinite experience from the UK highlights the ease of use of the new injection system, which includes three micro iStents. The updated injector offers several ergonomic enhancements along with an unlimited number of firing clicks which provides added confidence and flexibility for ophthalmic surgeons. When all three stents are implanted, the system allows for 240-degree access to Schlemm’s canal, helping to optimise outflow through the collector channels.
A key scientific highlight from the meeting was the presentation of new MIGS safety data from a meta-analysis of 38,000 eyes, showing the strong safety profile of iStent trabecular micro-bypass stents.
Another major theme emphasised throughout the meeting – in both podium and booth presentations – was the importance of early surgical intervention in glaucoma patients, which may delay disease progression, making these patients easier to manage during their lifetime.
FURTHER INFORMATION:
Glaukos
W: www.glaukos.com/en-uk/
